MedTrace Logo

Psychopharmacology of Psilocybin in Cancer Patients

NCT00465595 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2018-07-19

Study results available
· View outcomes & findings →

Summary

This research is being done to study the psychological effects of psilocybin in cancer patients. Psilocybin is a naturally occurring substance found in some mushrooms that some cultures have used for centuries in religious practices.

Conditions

Interventions

DRUG

psilocybin

The dose of psilocybin received in the two sessions will range anywhere from low to high.

Sponsors & Collaborators

Principal Investigators

  • Roland R Griffiths, Ph.D. · Johns Hopkins School of Medicine, Psychiatry Dept.

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2014-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00465595 on ClinicalTrials.gov